Improving the response to cancer immunotherapy by reactivating the 'guardian of the genome'

Retrieved on: 2021-07-07 13:41:15

Tags for this article:

Click the tags to see associated articles and topics

Improving the response to cancer immunotherapy by reactivating the 'guardian of the genome'. View article details on hiswai:

Excerpt

The company is developing a p53 reactivator dubbed eprenetapopt (APR-246). The drug, used in tandem with AbbVie and Roche's Venclexta and ...

Article found on: www.fiercebiotech.com